OBJECTIVE: We examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS). METHOD: The TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment withfluoxetine, cognitive-behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission. RESULTS: At week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive-behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36. CONCLUSIONS: Most depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment.
RCT Entities:
OBJECTIVE: We examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS). METHOD: The TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission. RESULTS: At week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive-behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36. CONCLUSIONS: Most depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment.
Authors: L M Koran; A J Gelenberg; S G Kornstein; R H Howland; R A Friedman; C DeBattista; D Klein; J H Kocsis; A F Schatzberg; M E Thase; A J Rush; R M Hirschfeld; L M LaVange; M B Keller Journal: J Affect Disord Date: 2001-06 Impact factor: 4.839
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: James H Kocsis; A John Rush; John C Markowitz; Frances E Borian; David L Dunner; Lorrin M Koran; Daniel N Klein; Madhukar H Trivedi; Bruce Arnow; Gabor Keitner; Susan G Kornstein; Martin B Keller Journal: Psychopharmacol Bull Date: 2003
Authors: Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Karen Dineen Wagner; Adelaide S Robb; Robert L Findling; Jianqing Jin; Marcelo M Gutierrez; William E Heydorn Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112
Authors: Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Xianfeng Shi; Eun-Kee Jeong; Perry F Renshaw Journal: J Affect Disord Date: 2011-08-09 Impact factor: 4.839
Authors: Laura J Dietz; Rebecca J Weinberg; David A Brent; Laura Mufson Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-12-30 Impact factor: 8.829
Authors: John Curry; Susan Silva; Paul Rohde; Golda Ginsburg; Christopher Kratochvil; Anne Simons; Jerry Kirchner; Diane May; Betsy Kennard; Taryn Mayes; Norah Feeny; Anne Marie Albano; Sarah Lavanier; Mark Reinecke; Rachel Jacobs; Emily Becker-Weidman; Elizabeth Weller; Graham Emslie; John Walkup; Elizabeth Kastelic; Barbara Burns; Karen Wells; John March Journal: Arch Gen Psychiatry Date: 2010-11-01
Authors: Dana L McMakin; Thomas M Olino; Giovanna Porta; Laura J Dietz; Graham Emslie; Gregory Clarke; Karen Dineen Wagner; Joan R Asarnow; Neal D Ryan; Boris Birmaher; Wael Shamseddeen; Taryn Mayes; Betsy Kennard; Anthony Spirito; Martin Keller; Frances L Lynch; John F Dickerson; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-03-03 Impact factor: 8.829
Authors: Betsy D Kennard; Graham J Emslie; Taryn L Mayes; Paul A Nakonezny; Jessica M Jones; Aleksandra A Foxwell; Jessica King Journal: Am J Psychiatry Date: 2014-10 Impact factor: 18.112